HC Wainwright Predicts Xeris Biopharma FY2026 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Research analysts at HC Wainwright increased their FY2026 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Friday, November 6th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.14 per share for the year, up from their prior estimate of $0.04. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.07 per share. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2026 earnings at $0.06 EPS, FY2027 earnings at $0.13 EPS and FY2030 earnings at $1.03 EPS.

Several other research firms have also weighed in on XERS. Piper Sandler restated a “neutral” rating and set a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research report on Friday. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, November 4th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 target price (up from $18.00) on shares of Xeris Biopharma in a research note on Friday. Finally, Barclays increased their target price on shares of Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.20.

Xeris Biopharma Trading Up 4.3%

NASDAQ XERS opened at $15.86 on Tuesday. The business’s fifty day moving average is $9.77 and its 200-day moving average is $7.66. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The stock has a market capitalization of $2.89 billion, a price-to-earnings ratio of -317.14 and a beta of 0.61. Xeris Biopharma has a one year low of $5.25 and a one year high of $15.94.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The firm had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million.

Insider Transactions at Xeris Biopharma

In related news, insider Beth Hecht sold 25,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $12.49, for a total transaction of $312,250.00. Following the completion of the transaction, the insider owned 1,559,208 shares in the company, valued at $19,474,507.92. The trade was a 1.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 173,332 shares of company stock worth $1,721,471. 4.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

Several hedge funds have recently made changes to their positions in the company. Royce & Associates LP raised its holdings in Xeris Biopharma by 27.5% in the third quarter. Royce & Associates LP now owns 588,178 shares of the company’s stock worth $5,623,000 after purchasing an additional 127,025 shares in the last quarter. Knights of Columbus Asset Advisors LLC purchased a new position in Xeris Biopharma during the third quarter valued at $1,275,000. StoneX Group Inc. purchased a new position in Xeris Biopharma during the third quarter valued at $142,000. Pictet Asset Management Holding SA lifted its position in Xeris Biopharma by 13.7% during the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company’s stock valued at $326,000 after buying an additional 4,108 shares during the period. Finally, AlphaCentric Advisors LLC boosted its holdings in shares of Xeris Biopharma by 4.2% during the 3rd quarter. AlphaCentric Advisors LLC now owns 48,489 shares of the company’s stock valued at $464,000 after buying an additional 1,940 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors.

Key Stories Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for FY2026 to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The firm reiterated its Buy rating and $18 price target. Xeris analyst estimates
• Positive Sentiment: Wall Street Zen upgraded Xeris, while Oppenheimer reiterated its Outperform rating; another report says the consensus brokerage view is Moderate Buy. Wall Street Zen upgrade Brokerage consensus Oppenheimer rating
• Neutral Sentiment: Piper Sandler reiterated a Neutral rating, tempering the otherwise positive analyst commentary. Piper Sandler rating

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative.

The company also develops drug-delivery technologies intended to make medicines easier to store and administer.